CTOs on the Move

Celmatix

www.celmatix.com

 
Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.celmatix.com
  • 14 Wall Street Suite 16D
    New York, NY USA 10005
  • Phone: 646.389.0245

Executives

Name Title Contact Details
Mark Adams
Chief Information Officer Profile

Similar Companies

Tactiva Therapeutics

Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.

AmnioLife

AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales.

Xpention Genetics Inc

Xpention Genetics Inc is a Conifer, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gen Trak (Main)

Gen Trak (Main) is a Liberty, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LEXEO Therapeutics

LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases.